AUPH Q1 2022 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M+2266.0% YoY

Gross Profit

$21M98.8% margin

Operating Income

-$38M-175.2% margin

Net Income

-$38M-174.0% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

-7.6%

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$47M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$507M

Total Liabilities

$59M

Stockholders' Equity

$448M

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$914,000	+2266.0%
Gross Profit	$21M	$866,000	+2367.6%
Operating Income	-$38M	-$51M	+25.0%
Net Income	-$38M	-$50M	+25.3%

Revenue Segments

Product

$21M99%

License

$133,0001%